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From a historical point of view, adequate treatment for dyslipidemia has been discussed and changed for long. There are recently four 
common broadly used agents, which are I) statins, II) n-3 unsaturated fatty acids, III) ezetimibe and IV) fibrates. In this article, recent 
topics concerning dyslipidemia and these agents would be described.  
When evaluating the effect of medical agents, it is generally expressed by the event occurrence rate of the active drug to placebo. This is 
shown by the numerical value of the Hazard Ratio (HR). However, this biomarker cannot indicate how long the event can be delayed in 
the future. Under such circumstances, an impressive study on statins has been reported. 
Firstly, statin agents have been broadly used for long. There is a study summarized from 16 Randomized Controlled Trials (RCTs) for 
statin administration [1]. As a result, the average survival time was prolonged by 12.6 days (95% CI: 7.1-18.0) by the statin administration. 
Furthermore, it showed 10.2 days for the primary preventive group and 17.4 days for the secondary preventive group [1].  
Two papers have been recently published on the efficacy of statins for the elderly. One is a paper that analyzed 28 RCTs [2]. The subjects 
included 186,854 patients with a median follow-up of 4.9 years. When the value of LDL-C decreased by 1.0 mmol/L (38.7 mg/dL), the 
ratio of major cardiovascular events decreased by 21% (Rate Ratio, RR: 0.79). This reduction in risk shows a similar trend at almost all 
ages. As their age became higher, the effective degree became lower. There was no statistically significant difference in the primary 
prevention group for over 70 years. 
Another study was a summary of 23 meta-analyses investigating changes in lipids and cardiovascular outcomes in 65 years and older 
60,194 subjects [3]. As a result, the administration of statins for primary prevention reduced coronary artery disease (RR: 0.79) and 
myocardial infarction (RR: 0.45), while no significant changes in total mortality (RR: 0.95) and cardiovascular fat (RR: 1.01). There was 
no significant risk reduction for stroke (RR: 0.78). Besides, the administration of statins for secondary prevention significantly reduced 
total death (RR: 0.80), cardiovascular disease (RR: 0.68), myocardial infarction (RR: 0.68) and revascularization (RR: 0.68). On the other 
hand, fibrate did not show a significant risk reduction in stroke, cardiovascular death or cardiovascular disease. 
There was a compared report for continuation and discontinuation groups with statin treatment [4]. A total of 120,173 patients with good 
adherence were followed up for 2.4 years on average. The discontinued group showed a 33% increase in hospitalization for all 
cardiovascular events (HR: 1.33), associated with hospitalization for coronary events (HR: 1.46) and cerebrovascular disease events (HR: 

























As a result, the influencing factors included low income (Odds Ratio, OR: 1.20), smoking (OR: 1.14), higher medical payment (OR: 1.61), 
multidrug combination (OR: 1.04), dementia (OR: 1.18), respiratory disease (OR: 1.05) [5]. 
There has been a novel project, which is Statins in Reducing Events in the Elderly (STAREE). It is a world-first study conducted by 
Universities across Australia on the effects of statins on healthy aging [6]. The characteristic points would be I) it is funded by public health 
research grants, II) it does not accept funding from pharmaceutical companies to reduce influence and bias, III) its findings will directly 
benefit current and future generations of Australians [6].  
Secondly, n-3 unsaturated fatty acids have been used. As to the efficacy for cardiovascular disease, there have been some reports of a 
randomized, double-blind, placebo-controlled trial. 
The first is the Vitamin D and Omega-3 Trial (VITAL) [7]. A total of 25,871 subjects were compared between the n-3 administration group 
and the placebo group. Major cardiovascular events (a composite of myocardial infarction, stroke or death from cardiovascular causes) 
were examined. At a median follow-up of 5.3 years, there were no significant differences between the two groups (HR: 0.92) [7]. 
The second is the Reduction of Cardiovascular Events with EPA – Intervention Trial (REDUCE-IT) [8]. It was a multicenter, randomized, 
double-blind, placebo-controlled trial, with 8,179 subjects taking statins. For the EPA group, icosapent ethyl 4 g/day was provided for 
comparison with the placebo group. Outcomes were studied as the primary endpoint, including a composite of cardiovascular death, 
nonfatal myocardial infarction, nonfatal stroke, coronary revascularization or unstable angina. Following both groups for 4.9 years, the risk 
for cardiovascular events was significantly reduced by 17.2% in the EPA group and 22.0% in the placebo group (HR: 0.75) without a 
significant difference between them [8].    
Furthermore, there is a systematic review meta-analysis of the RCT. The purpose was to examine the effect of Omega-3 Fatty acids on 
mortality, morbidity and adverse events in patients with acute myocardial infarction (AMI) [9]. The results from 24,414 patients in 10 studies 
showed no significant difference in total mortality (RR: 0.86), but significantly reduced risk in cardiovascular death (RR: 0.77) and acute 
myocardial infarction (RR: 0.77) [9].  
On the other hand, there is a Study of Cardiovascular Events in Diabetes (ASCEND), in which the effect of n-3 unsaturated fatty acid was 
not observed [10]. A total of 15,480 diabetic patients without a history of cardiovascular disease were followed for 7.4 years. As a result, 
the occurrence of serious vascular events was 8.9% in the n-3 group and 9.2% in the placebo group, with no significant difference (RR: 
0.97) [10].   
Regarding the above reports of n-3 unsaturated fatty acids, the results differ due to various factors such as differences in subject 
characteristics, differences in high risk, the dosage of ethyl icosapentate and so on. These studies have different method protocols. In 
VITAL and ASCEND, subjects showed a lower risk of cardiovascular events and received 1 g/day of n-3 unsaturated fatty acids [7,10]. 
On the other hand, in REDUCE-IT, subjects showed a higher risk for cardiovascular events and received 4 g/day of ethyl icosapentate 
[8]. Thus, it is necessary to compare the details of the intervention content for several studies. Based on the results of REDUCE-IT, 
American Heart Association (AHA) has rated n-3 unsaturated fatty acids as an effective and safe option to reduce triglyceride as 
monotherapy or as an adjunct to other lipid-lowering drugs [11].  
The third agent is ezetimibe. There have been reports of RCTs such as SEAS [12], SHARP [13] and IMPROVE-IT [14]. Recently, a meta-
analysis of 26 RCTs has been reported [15]. Whether the combination of statins and ezetimibe has a benefit over statin alone is still under 
investigation. 
Recent topics include reports of the efficacy of ezetimibe in the elderly [16]. It is a multicenter, prospective, randomized, open-label, 
blinded end-point evaluation conducted at 363 medical institutions in Japan. It was Ezetimibe Lipid-Lowering Trial on Prevention of 
Atherosclerotic Cardiovascular Disease in 75 or Older (EWTOPIA 75). Totally 3,796 subjects were randomly assigned to the ezetimibe 
group (10 mg once daily) versus the control group. The primary outcome was a composite of sudden cardiac death, myocardial infarction, 
coronary revascularization or stroke. As a result of follow up to 4.1 years, the ezetimibe group showed a significant reduction of the primary 
outcome (HR: 0.66). Secondary outcomes showed significantly reduced values, which were the incidences of composite cardiac events 
(HR: 0.60) and coronary revascularization (HR: 0.38) [16]. However, it should be noted that this study is an open-label study and soft 
endpoint includes coronary revascularization. Therefore, effectiveness may have been overestimated. 
Fourth agents are fibrates. They have a potentially beneficial effect on primary prevention, secondary prevention and reduced risk of 
cardiovascular disease. However, the clinical effect for total and cardiovascular mortality have not been identified [17,18]. Furthermore, 
Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors have also been reported to reduce cardiovascular risk, but their effect on 
mortality risk has been uncertain [19,20].  
In summary, recent topics on oral agents for dyslipidemia were introduced. We hope that this article will serve as a reference for the drug 
treatment of patients with various conditions in the future.  
 




Conflict of interest 
The author declares no conflict of interest. 
 
Funding 
There was no funding received for this paper.  
 
References 
1. Hansen MR, Hróbjartsson A, Pottegård A, Damkier P, Larsen KS, Madsen KG, et al. Postponement of death by statin use: a systematic review and 
meta-analysis of randomized clinical trials. J Gen Intern Med 2019;34:1607-14.  
2. Cholesterol Treatment Trialists' Collaboration. Efficacy and safety of statin therapy in older people: a meta-analysis of individual participant data from 28 
randomised controlled trials. Lancet 2019;393:407-15. 
3. Ponce OJ, Larrea-Mantilla L, Hemmingsen B, Serrano V, Rodriguez-Gutierrez R, Spencer-Bonilla G, et al. Lipid-lowering agents in older individuals: a 
systematic review and meta-analysis of randomized clinical trials. J Clin Endocrinol Metab 2019;104:1585-94.  
4. Giral P, Neumann A, Weill A, Coste J. Cardiovascular effect of discontinuing statins for primary prevention at the age of 75 years: a nationwide population-
based cohort study in France. Eur Heart J 2019;40:3516-25. 
5. Ofori-Asenso R, Jakhu A, Curtis AJ, Zomer E, Gambhir M, Jaana Korhonen M, et al. A systematic review and meta-analysis of the factors associated 
with nonadherence and discontinuation of statins among people aged ≥65 years. J Gerontol A Biol Sci Med Sci 2018;73:798-805. 
6. Statins in reducing events in the elderly (STAREE) [Internet]. Available from: http://www.staree.org.au/. 
7. Manson JE, Cook NR, Lee IM, Christen W, Bassuk SS, Mora S, et al. Marine n-3 fatty acids and prevention of cardiovascular disease and cancer. N 
Engl J Med 2019;380:23-32. 
8. Bhatt DL, Steg PG, Miller M, Brinton EA, Jacobson TA, Ketchum SB, Doyle RT Jr, Juliano RA, Jiao L, Granowitz C, Tardif JC, Ballantyne CM; REDUCE-
IT Investigators. Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia. N Engl J Med 2019;380:11-22. 
9. Popoff F, Balaciano G, Bardach A, Comandé D, Irazola V, Catalano HN, et al. Omega 3 fatty acid supplementation after myocardial infarction: a 
systematic review and meta-analysis. BMC Cardiovasc Disord 2019;19:136.  
10. Bowman L, Mafham M, Wallendszus K, Stevens W, Buck G, Barton J, Murphy K, Aung T, Haynes R, Cox J, Murawska A, Young A, Lay M, Chen F, 
Sammons E, Waters E, Adler A, Bodansky J, Farmer A, McPherson R, Neil A, Simpson D, Peto R, Baigent C, Collins R, Parish S, Armitage J; ASCEND 
Study Collaborative Group. Effects of n-3 fatty acid supplements in diabetes mellitus. N Engl J Med 2018;379:1540-50.  
11. Skulas-Ray AC, Wilson PWF, Harris WS, Brinton EA, Kris-Etherton PM, Richter CK, et al. Omega-3 fatty acids for the management of 
hypertriglyceridemia: a science advisory from the American Heart Association. Circulation 2019;140:673-91. 
12. Rossebø AB, Pedersen TR, Boman K, Brudi P, Chambers JB, Egstrup K, Gerdts E, Gohlke-Bärwolf C, Holme I, Kesäniemi YA, Malbecq W, Nienaber 
CA, Ray S, Skjaerpe T, Wachtell K, Willenheimer R; SEAS Investigators. Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis. N 
Engl J Med 2008;359:1343-56. 
13. Baigent C, Landray MJ, Reith C, Emberson J, Wheeler DC, Tomson C, Wanner C, Krane V, Cass A, Craig J, Neal B, Jiang L, Hooi LS, Levin A, Agodoa 
L, Gaziano M, Kasiske B, Walker R, Massy ZA, Feldt-Rasmussen B, Krairittichai U, Ophascharoensuk V, Fellström B, Holdaas H, Tesar V, Wiecek A, 
Grobbee D, de Zeeuw D, Grönhagen-Riska C, Dasgupta T, Lewis D, Herrington W, Mafham M, Majoni W, Wallendszus K, Grimm R, Pedersen T, Tobert 
J, Armitage J, Baxter A, Bray C, Chen Y, Chen Z, Hill M, Knott C, Parish S, Simpson D, Sleight P, Young A, Collins R; SHARP Investigators. The effects 
of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomized 
placebo-controlled trial. Lancet 2011;377:2181-92.  
14. Cannon CP, Blazing MA, Giugliano RP, McCagg A, White JA, Theroux P, Darius H, Lewis BS, Ophuis TO, Jukema JW, De Ferrari GM, Ruzyllo W, De 
Lucca P, Im K, Bohula EA, Reist C, Wiviott SD, Tershakovec AM, Musliner TA, Braunwald E, Califf RM; IMPROVE-IT Investigators. Ezetimibe added to 
statin therapy after acute coronary syndromes. N Engl J Med 2015;372:2387-97. 
15. Zhan S, Tang M, Liu F, Xia P, Shu M, Wu X. Ezetimibe for the prevention of cardiovascular disease and all-cause mortality events. Cochrane Database 
Syst Rev 2018;11:CD012502.  
16. Ouchi Y, Sasaki J, Arai H, Yokote K, Harada K, Katayama Y. Ezetimibe lipid-lowering trial on prevention of atherosclerotic cardiovascular disease in 75 
or older (EWTOPIA 75): a randomized, controlled trial. Circulation 2019;140:992-1003. 
17. Jakob T, Nordmann AJ, Schandelmaier S, Ferreira-González I, Briel M. Fibrates for primary prevention of cardiovascular disease events. Cochrane 
Database Syst Rev 2016;11:CD009753. 
18. Wang D, Liu B, Tao W, Hao Z, Liu M. Fibrates for secondary prevention of cardiovascular disease and stroke. Cochrane Database Syst Rev 
2015;10:CD009580. 
19. Sabatine MS, Giugliano RP, Keech AC, Honarpour N, Wiviott SD, Murphy SA, Kuder JF, Wang H, Liu T, Wasserman SM, Sever PS, Pedersen TR; 
FOURIER Steering Committee and Investigators. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med 
2017;376:1713-22.  
20. Schmidt AF, Pearce LS, Wilkins JT, Overington JP, Hingorani AD, Casas JP. PCSK9 monoclonal antibodies for the primary and secondary prevention 
of cardiovascular disease. Cochrane Database Syst Rev 2017;4:CD011748.  
 
